BioSpace News Archive

Gamida Cell Ltd. today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.

Coherus BioSciences, Inc. today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.

Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution.

Axalbion presented positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough, in an oral session at the American Thoracic Society (ATS) 2023 International Conference, being held in Washington, DC, from May 19 - 24, 2023.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.

ATCOR Medical announced it has launched a single-center retrospective study of 2,000 hypertensive patients to identify associated care outcomes resulting from the routine monitoring of central aortic blood pressure and peripheral blood pressure.

Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients with relapsed/refractory Lymphoma.

Eli Lilly and Company released its latest Environmental, Social and Governance report showing progress towards the company’s ambitious sustainability goals, which are critical to maintaining a strong and resilient company.

Foundation for Sarcoidosis Research is proud to announce the release of the Ignore No More Campaign on Clinical Trials Diversity:Advancing Clinical Trial Equity for Black Patients with Sarcoidosis White Paper which summarizes the findings and recommendations from an IRB-approved national survey of Black Americans to get a better understanding of the challenges and experiences they face in considering and participating in clinical trials.